From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization

The evolution of percutaneous coronary intervention has improved the outcomes of patients with coronary artery disease, but conventional drug-eluting stents remain limited by late adverse events, reduced vessel compliance, and the inability to restore physiological function. The DynamX coronary bioadaptor aims to address these issues by combining the mechanical performance of drug-eluting stents with a bioadaptive mechanism that restores natural vessel motion. The device features a cobalt-chromium scaffold connected by bioresorbable polymer elements that degrade 6 months after implantation. This process unlocks helical strands, enabling vessel pulsatility, compliance, and adaptive remodeling while maintaining lumen integrity. Preclinical studies demonstrated reduced vessel stress and restored physiological rotational motion. In the DYNAMIX (12-Month Clinical and Imaging Outcomes of the Uncaging Coronary DynamX Bioadaptor System) study, patients exhibited increased vessel area without lumen loss, optimal strut apposition, and complete neointimal coverage at 12 months. The small BIOADAPTOR-RCT (Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Versus Zotarolimus-Eluting Drug-Eluting Stent) showed noninferiority to drug-eluting stents with superior late lumen preservation and reduced neointimal hyperplasia. The larger INFINITY-SWEDEHEART (Percutaneous Coronary Intervention With a Bioadaptor Compared to a Contemporary Drug-Eluting Stent) trial confirmed low target-lesion failure rates and a plateauing of adverse events after 6 months, highlighting the benefits of vessel motion restoration. The DynamX coronary bioadaptor may represent a significant advancement in percutaneous coronary intervention by providing early mechanical support and restoring vessel function. Further studies on complex anatomy and long-term outcomes are needed to further define its role in interventional cardiology.